Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2002

View Archived Issues

Three series of MMP inhibitors prepared and tested at former Warner-Lambert

Antimyeloma efficacy of PS-341 in a human plasmacytoma xenograft model

Antitumor activity of IDN-5109 against hormone-refractory prostate cancer

Antisense oligonucleotide to ICAM-1 ameliorates chronic intestinal inflammation in transgenic rats

NXY-059 exerts neuroprotective effects in rat model of acute stroke

Deltagen discovers novel antibody target for potential treatment of rheumatoid arthritis

Ceregene receives SBIR grant for Alzheimer's disease gene therapy research

Novel series of PDE4 inhibitors in early development at Altana

New mGluR1 modulators for use in neuropathic pain and other disorders

Bayer researchers describe novel factor Xa inhibitors

Scientists at Ajinomoto synthesize inhibitors of activation of inflammatory factors

Amine salts of alphavbeta3 antagonist and their use in osteoporosis claimed by Merck

Novel antiproliferative macrolides prepared by Kosan researchers

CRF antagonists in early development at Neurocrine Biosciences

CV Therapeutics presents novel fatty acid oxidation inhibitors for cardiovascular disorders

Pfizer identifies potent, selective, orally active sorbitol dehydrogenase inhibitor

Phase II results of dapsone in Alzheimer's disease

Second phase of RADIUS trial initiated

Phase II Multikine trial in head and neck cancer completes enrollment

Small-molecule MC4 receptor agonist with effects on food intake and erectile activity

First nonpeptide urotensin-II receptor agonist reported recently

Preclinical antibacterial activity, pharmacokinetics and toxicity of new PDF inhibitor

Well-established antiparasitic agent now reported to possess potent antitumor activity

New data on the safety and efficacy of topical tacrolimus in atopic dermatitis

Alefacept reported to be a valid therapeutic option for chronic psoriasis

Pegasys approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...